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Background: Inhibition of kinases involved in the DNA damage response sensitizes cells to genotoxic agents by
abrogating checkpoint-induced cell cycle arrest. CHK1 and WEE1 act in a pathway upstream of CDK1 to inhibit cell
cycle progression in response to damaged DNA. Therapeutic targeting of either CHK1 or WEE1, in combination with
chemotherapy, is under clinical evaluation. These studies examine the overlap and potential for synergy when CHK1
and WEE1 are inhibited in cancer cell models.
Methods: Small molecules MK-8776 and MK-1775 were used to selectively and potently inhibit CHK1 and
WEE1, respectively.
Results: In vitro, the combination of MK-8776 and MK-1775 induces up to 50-fold more DNA damage than either
MK-8776 or MK-1775 alone at a fixed concentration. This requires aberrant cyclin-dependent kinase activity but
does not appear to be dependent on p53 status alone. Furthermore, DNA damage takes place primarily in S-phase
cells, implying disrupted DNA replication. When dosed together, the combination of MK-8776 and MK-1775
induced more intense and more durable DNA damage as well as anti-tumor efficacy than either MK-8776 or
MK-1775 dosed alone. DNA damage induced by the combination was detected in up to 40% of cells in a treated
xenograft tumor model.
Conclusions: These results highlight the roles of WEE1 and CHK1 in maintaining genomic integrity. Importantly, the
strong synergy observed upon inhibition of both kinases suggests unique yet complimentary anti-tumor effects of
WEE1 and CHK1 inhibition. This demonstration of DNA double strand breaks in the absence of a DNA damaging
chemotherapeutic provides preclinical rationale for combining WEE1 and CHK1 inhibitors as a cancer
treatment regimen.Background
Small molecule inhibitors against checkpoint kinases con-
stitute a promising class of targeted cancer therapeutics and
many are currently under preclinical or even clinical evalu-
ation. The role of checkpoint kinases is to respond to stress,
typically damaged DNA or aberrant chromosomal struc-
ture, and stop the cell division process long enough for the
damage to be repaired. These “checkpoints” prevent cells
from dividing and perpetuating mutations or chromosomal* Correspondence: stuart_shumway@merck.com
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reproduction in any medium, provided the oranomalies that would otherwise lead to cellular lethality.
The rationale for inhibiting checkpoint kinases is to accu-
mulate irreparable and fatal genetic lesions by compromis-
ing the DNA damage response (DDR) and forcing
premature or untimely cell division. Notable examples in-
clude the mitotic checkpoint kinases Aurora A and B,
checkpoint kinase 1 (CHK1), CHK2, ATR, and WEE1.
Several CHK1 inhibitors have been employed in early
stage clinical trials [1,2]. Notably, MK-8776 (also referred to
as SCH-900776), a CHK1-selective inhibitor, is under evalu-
ation in phase I studies in combination with gemcitabine or
cytarabine [3]. Only one inhibitor of WEE1 has been
explored clinically. MK-1775, a potent and selective inhibi-
tor of WEE1, achieved favorable phase I pharmacokineticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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boplatin, cisplatin, and gemcitabine, and is under further in-
vestigation as a chemosensitizer in a phase II trial [4].
CHK1 is an essential serine/threonine kinase involved
in S- and G2/M-phase checkpoints [5-9], replica-
tion initiation and fork stability [10-12], homologous
recombination repair [13,14], and entry into mitosis in
normal cycling cells [15]. Importantly, CHK1 is neces-
sary for unperturbed DNA replication and cell cycle co-
ordination even in the absence of any exogenous insult
[16]. The cytotoxic nature of CHK1 knockdown or in-
hibition, either alone or in combination with DNA-
damaging therapeutics, has been described extensively
(for review, see [2]).
WEE1 is an essential tyrosine kinase that is also
involved in S and G2/M checkpoints. WEE1 directly
phosphorylates and inhibits CDK1 and CDK2 at the
conserved tyrosine 15 residue, affecting entry into mi-
tosis as well as coordination of DNA replication events.
WEE1 is therefore critical for properly timing cell div-
ision in unperturbed cells, and loss of WEE1 results
in chromosomal aneuploidy and accumulated DNA
damage [17]. Additionally, WEE1 is critical to S- and
G2/M-phase checkpoint responses following DNA dam-
age as well as in unperturbed cells [18-20]. Interfering
with WEE1 has been shown to repress cancer cell prolif-
eration and sensitize theme to the anti-tumor growth
effects of DNA-damaging chemotherapeutics or radi-
ation therapy [21-28].
Considering the overlapping roles of WEE1 and CHK1
in mitotic entry, DNA replication, and the DDR, we
sought to determine whether inhibition of these two
kinases was redundant or complimentary. We demon-
strate here that combination of a CHK1 inhibitor,
MK-8776, and a WEE1 inhibitor, MK-1775, results in syn-
ergistic inhibition of cell proliferation in several human
tumor cell lines. Minimal concentrations of the drugs
required to block cell proliferation lead to a greater than
additive increase of γH2AX, a marker of DNA double
strand breaks (DSB). This occurs primarily in S-phase
cells, suggesting that the unique combination of CHK1
and WEE1 inhibitors disrupts DNA replication and its
associated checkpoint. Pharmacodynamic (PD) analysis in
xenograft tumors supports this notion, showing an in-
crease in both the percentage of cells containing DNA
damage as well as the duration of the DDR. Consistent
with the PD data, we demonstrate that the combination of
CHK1 and WEE1 inhibitors leads to greater-than-additive
tumor growth inhibition in two human tumor xenograft
models. Collectively, these data demonstrate the synergis-
tic anti-tumor effects of pharmacological WEE1 and
CHK1 inhibition and highlight the potential of this unique
combination in treating human cancer independently of
chemotherapeutic drugs.Results and discussion
Inhibition of WEE1 and CHK1 causes synergistic inhibition
of cell proliferation
In a drug combination screen of 39 cell lines, the pairing of
MK-1775 (WEE1 inhibitor) and MK-8776 (CHK1 inhibitor)
demonstrated synergistic inhibition of proliferation across
the majority of cell lines (Additional file 1 Figure S1). To
further validate the ability of the two drugs to potentiate the
activity of one another, we performed 9-point titrations of
each in the added presence of increasing, but fixed, concen-
trations of the complimentary drug in eight cell lines
(Figure 1A, B). In the A2058 melanoma cancer cell line,
MK-1775 caused complete growth inhibition with an aver-
age EC50 of 225 nM. The addition of MK-8776 at concen-
trations that by themselves do not affect A2058
proliferation (37.5 or 75 nM) caused a shift of the MK-1775
response curve, effectively lowering the EC50 of MK-1775
(Figure 1A). Addition of 150 nM MK-8776 reduced the
MK-1775 EC50 by 5-fold to an average of 45 nM. EC50 shifts
in other cell lines fell between 1.9- and 9.1-fold (Figure 1A
and data not shown). When the converse experiment was
performed and MK-8776 was titrated over a range of fixed
amounts of MK-1775 in A2058 cells, we again observed
leftward shifts in EC50 curves as well as a dose-dependent
increase in the maximum cell growth inhibition attained at
the highest concentration of MK-8776 (Figure 1B). Synergy
values for MK-1775 and MK-8776 were notably low in two
primary cell lines examined, human mammary epithelial
cells and human renal epithelial cells (Additional file 1
Figure S1 and Additional file 2 Figure S2).
Inhibition of WEE1 and CHK1 leads to aberrant CDK1
and/or CDK2 activity, the possible mechanism underlying
the deleterious effects on actively dividing tumor cells. Be-
cause of the possible overlap in MK-1775 and MK-8776
mechanisms of action, we carried out sham synergy
experiments. We titrated MK-1775 over 75 nM of MK-
1775 itself or the CHK1 inhibitor MK-8776 and confirmed
that MK-1775 did not cause its response curve to shift
whereas MK-8776 caused a robust potency shift
(Figure 1C). These findings highlight the complimentary,
non-overlapping mechanisms underlying the in vitro syn-
ergy of WEE1 and CHK1 inhibitors.
Cell cycle disruption results from WEE1 and CHK1
inhibition
As negative regulators of CDKs, both WEE1 and CHK1
coordinate passage through the cell cycle. Therefore, we
determined the effects of simultaneous inhibition of
WEE1 and CHK1 on the cell cycle profile of asynchron-
ously growing cell populations. We selected two cell lines
where synergy was observed, NCI-H2009 NSCLC and
Su.86.86 pancreatic cancer cells, and used concentrations
of the two inhibitors that had little effect on cell prolifera-
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Figure 1 Restraint of cell proliferation by WEE1 inhibitor is potentiated by a CHK inhibitor, and vice versa. A, The WEE1 inhibitor MK-
1775 was titrated over A2058 cells in addition to either vehicle (DMSO), or the indicated fixed concentration of the CHK1 inhibitor, MK-8776.
Tabulated EC50 concentrations for MK-1775 in the presence of vehicle or 150 nM fixed concentration of MK-8776 are presented in the lower
panel for seven different cell lines. Fold change in EC50 values between vehicle treated and MK-8776 treated cells illustrates the potentiation of
MK-1775 by MK-8776. B, Experiment was performed on A2058 cells as described in (A) with the exception that MK-8776 was titrated over either
vehicle (DMSO) or fixed concentrations of MK-1775. C, As described in (A), A2058 cells were treated with a gradient of MK-1775 in the added
presence of vehicle or 150 nM fixed concentration of MK-1775 or MK-8776.
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thelial (HRE) cells and normal human mammary epithelial
cells (HMEC), which did not score high in the combin-
ation synergy screen (Additional file 1 Figure S1) and were
unresponsive to the concentrations of inhibitors used
(Figure 2, top panel, 150 nM MK-1775 and 500 nM
MK-8776). In all the cells tested, MK-1775 had no dis-
cernible effect on the cell cycle profile, whereas MK-8776
caused an increase in the number of G1/S-phase cells in
the cancer lines (Figure 2, bottom panels). Notably, the
combination of MK-1775 and MK-8776 led to a dramatic
accumulation of cells with G1/S-phase DNA content in
both tumor lines (Figure 2, bottom row). Again, this effect
was not seen in either of the normal cell populations
tested, consistent with published observations that WEE1
knockdown is more deleterious in transformed cells than
in non-transformed cells [27].
Inhibition of WEE1 and CHK1 leads to synergistic
accumulation of DNA damage
Inactivating mutations of p53 can impair the G1 check-
point arrest that typically follows DNA damage. Due toa compromised G1 checkpoint, it is suggested that p53-
deficient tumor cells are more dependent on the G2
checkpoint and therefore more likely to be sensitized to
DNA damaging agents by G2 checkpoint modulators,
i.e. WEE1 or CHK1 inhibitors. Mutational status of p53
was found for 31 of the 39 cancer cell lines screened and
these lines were analyzed for synergy of the MK-1775
and MK-8776 combination (Figure 3A). Synergy scores
ranged from 0 (no synergy) to > 0.4 (strong synergy)
among both p53 wild type and p53 mutant cell lines, but
we failed to observed any difference in synergy among
the two groups. The same cell panel did demonstrate a
trend toward greater overall sensitivity to the MK-1775
plus MK-8776 combination among p53 mutant lines
(Figure 3B). Two p53 wild type or null isogenic cell line
pairs demonstrated similar synergy and overall response
to the MK-1775 and MK-8776 combination (Figure 3C).
Loss of either WEE1 or CHK1 function through siRNA
depletion or small molecule inhibition results in an accumu-
lation of DNA damage. Therefore, we considered the likeli-
hood that combining MK-1775 with MK-8776 might result



















































Figure 2 MK-1775 combined with MK-8776 results in G1/S-phase accumulation. Cancer cell lines or primary human epithelial cells were
treated with vehicle control (DMSO), 150 nM MK-1775, 500 nM MK-8776, or both compounds for 72 hours and analyzed for cell viability (top
panels). Values are normalized and graphed as viable percentage of treated cells relative to DMSO treated control cells. Bottom panels, cells were
treated with the same concentrations of MK-1775 and MK-8776 used in the upper panels but only for 24 hours before being harvested and
analyzed by flow cytometry for DNA content.
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concentrations of MK-1775 and MK-8776 that alone had
limited effect in a cell proliferation assay, but when com-
bined led to >80% growth inhibition (Figure 4A, top panel).
We selected three sensitive cell lines where the combination
of MK-1775 and MK-8776 was effective: A2058 (p53 mu-
tant) melanoma cells treated with 125 nM MK-1775 and
150 nM MK-8776, HT-29 (p53 mutant) colorectal cancer
cells treated with 125 nM MK-1775 and 300 nM MK-8776,
and LoVo (p53 wild type) colorectal cancer cells treated with
40 nM MK-1775 and 75 nM MK-8776. Continuous expos-
ure to either drug individually for as long as 48 hours was
unable to robustly induce γH2AX staining, appearing in
only 10% or less of treated cells (Figure 4A, middle panel).
When combined, however, the same concentrations of MK-
1775 and MK-8776 demonstrated synergistic induction of
γH2AX in as many as 45% to 75% of treated cells, which
was maximally induced by 24 hours.
In addition to their effects on DNA metabolism, both
WEE1 and CHK1 inhibitors are known to disrupt the G2/M cell cycle checkpoint and accelerate mitotic entry. There-
fore, to determine whether premature mitosis could con-
tribute to the synergism of MK-1775 and MK-8776, the
mitotic index of treated cells was scored using the mitotic
marker phosphorylated serine 28 of histone H3 (pHH3). In
both HT-29 and, to a lesser extent, A2058 cells, we
observed a more-than-additive increase of pHH3 positive
cells in the combination treated population, indicating that
accelerated or premature mitosis can indeed result from
combination treatment (Figure 4A, lower panel). Interest-
ingly, however, no increase in pHH3 positive cells was
observed when LoVo cells were treated with the combin-
ation despite equally robust inhibition of cell proliferation
and induction of DNA damage as in the A2058 and HT-29
cells. This suggests that DNA damage is the primary mech-
anism underlying the cytotoxic synergy of WEE1 and
CHK1 inhibitors, whereas premature mitosis may or may
not contribute as a secondary mechanism of action.
To better determine whether DNA damage is associated
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p53+/+ 0.333 0.132 2.5
p53-/- 0.235 0.092 2.6
p53+/+ 0.210 0.064 3.3







































Figure 3 Cellular p53 status does not predict synergy when MK-1775 is combined with MK-8776. A, Proliferation assays were performed
on cell lines treated with four concentrations each of MK-1775 and MK-8776 titrated against each other (see Additional file 1: Figure S1). Synergy,
calculated as the volumetric difference between the observed response and the predicted additive response (Bliss), was plotted for p53 wild type
cells (n=15) and cell lines harboring p53 mutations (n=16). B, As described in part A, except that fractional viability relative to DMSO treated
control cells from the proliferation assay was plotted for cell lines treated with 150 nM MK-1775 and 350 nM MK-8776. C, Parental and p53-
deleted HCT116 and RKO matched pair cells were treated in a proliferation assay with MK-1775 in the presence of either added vehicle (DMSO)
or 150 nM MK-8776. Results from the response curves were tabulated and synergy determined by fold change in MK-1775 EC50 values.
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of γH2AX or pHH3 (Figure 4B). We treated KPL-1 (p53
wild type), NCI-H460 (p53 wild type), and T47D (p53 mu-
tant) cells each with 150 nM MK-1775, 300 nM MK-8776,
or both. These drug concentrations are equal to or in ex-
cess of those used for the three sensitive cell lines. As
expected, only minimal effects were observed on cell via-
bility. In KPL-1 cells we observed induction of γH2AX,
though unlike all three sensitive lines, the DNA damage in
the combination treated sample was not maximally
induced by 24 hours, did not exceed 32%, and was not ob-
viously supra-additive. This cell line did not show an in-
crease in pHH3 positive cells when treated with the
combination. Neither NCI-H460 nor T47D cells showed
any appreciable evidence of DNA damage or premature
mitosis, supporting the notion that MK-8776 and MK-
1775 synergize to inhibit cell proliferation by inducing
DNA damage in sensitive cell lines.
DNA damage is present in the S-phase population of cells
and is CDK dependent
Both siRNA knockdown and pharmacologic inhibition of
WEE1 are known to result in damaged DNA specifically
in S-phase cells ([19], data not shown). Cell cycle analysis
based on DNA content of the three sensitive cell lines
above demonstrated that DNA damage caused by theMK-1775 and MK-8776 combination is detected in
S- phase (Figure 5). Detection of cleaved PARP in the
presence of the drug combination suggests apoptosis as a
result of DNA damage in sensitive cell lines (Figure 6A).
Since the only characterized substrates for WEE1 are
CDK1 and CDK2, we next questioned whether the ability
of WEE1 and CHK1 inhibition to result in DNA damage
was dependent on CDK activity. For these studies we
employed SCH-727965, a previously described potent in-
hibitor of CDK1, CDK2, CDK5, and CDK9 [29]. We
looked at phosphorylated serine 345 of CHK1 in the three
sensitive cell lines as a surrogate for an activated DNA
damage response [9]. As expected, pairing of MK-1775 and
MK-8776 at concentrations that induced γH2AX (Figure 5)
also led to the rapid phosphorylation of CHK1S345 and in-
duction of γH2AX (Figure 6B). Notably, this phospho-
CHK1S345 signal was reduced by a 30 minute pretreatment
of the CDK inhibitor, implying that aberrant CDK activity,
as a result of WEE1 and/or CHK1 inhibition, is required
for the drug combination to induce DNA damage. Al-
though we monitored acute induction of DNA damage, we
cannot exclude the possibility that CDK inhibition arrests
cell cycle progression, indirectly preventing DNA damage
following MK-1775 and MK-8776 treatment.
To ask whether MK-1775 and MK-8776 act coopera-





























































































































































Figure 4 Combined WEE1 and CHK1 inhibition at anti-proliferative concentrations leads to synergistic induction of DNA damage.
A, Concentrations of MK-1775 and MK-8776 were selected that alone have minimal effects on cell viability but in combination lead to inhibition
of cell proliferation. Concentrations used in each cell line were, for A2058: 125 nM MK-1775, 150 nM MK-8776; for HT-29: 125 nM MK-1775, 300
nM MK-8776; and for LoVo: 40 nM MK-1775, 75 nM MK-8776. Top panel, Cells were treated with DMSO, MK-1775, MK-8776, or both compounds
and viability for A2058, LoVo, and HT-29 cells was determined at 48 and 72 hours. Viability is shown as percentage of DMSO treated control cells.
Middle panel, Cells were treated as above and collected at 24 and 48 hours following drug addition. To assess DNA damage, the percentage of
γH2AX positive cells was determined by flow cytometry. Lower panel, Cells were treated as above and collected at 24 and 48 hours for mitotic
index analysis, calculated by determining the percentage pHH3 positive cells by flow cytometry. B, KPL-1, NCI-H460, and T47D cell lines were
treated with DMSO, 150 nM MK-1775, 300 nM MK-8776, or the combination of the two drugs and analyzed for viability, DNA damage, and
mitotic index as described in (A).
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tus at CDK1T14 and CDK1Y15 in LoVo cells treated alone
or in combination. As Figure 6C shows, treatment with
MK-1775 resulted in an expected decrease of phospho-
CDK1Y15, no detectable change in phospho-CDK1T14, and
slight induction of the DDR evident from phospho-
CHK1S345. Treatment with MK-8776 also induced the
phospho-CHK1S345 signal, which was even further
increased following treatment with the combination.
Interestingly, however, neither MK-8776 nor MK-8776 in
combination with MK-1775 led to further reduction of
phospho-CDK1Y15, suggesting that MK-8776 might be co-
operating with MK-1775 via modulation of downstream
effectors of CHK1 other than CDC25 phosphatases and
CDKs. This finding is consistent with the observed syn-
ergy of MK-1775 and MK-8776 and the notion that WEE1
and CHK1 carry out unique, yet complimentary, functions
in DNA replication and/or intra-S phase checkpoint
control.MK-1775 and MK-8776 lead to increased DNA damage in
xenograft models
Combination of MK-1775 and MK-8776 synergistically
induced DNA damage in vitro (Figure 4), so we next
examined its effect on DNA damage in vivo. Animals
bearing LoVo xenograft tumors received 2 days of twice
daily (BID) dosing of vehicle, MK-1775 (60 mpk), MK-
8776 (60 mpk), or the combination. Tumors were col-
lected at 2, 24, and 48 hours after the fourth and final
dose and subsequently analyzed by Western blot and
immunohistochemistry (IHC). Figure 7A shows that
when dosed alone, both MK-1775 and MK-8776 lead to
a transient increase in phospho-CHK1S345. Notably,
treatment with the combination resulted in a greater in-
duction of phospho-CHK1S345 at 2 hours, and unlike ei-
ther single agent alone, this effect was still evident at 24
hours after the final dose. Consistent with this observa-
tion, IHC results in Figure 7B demonstrate an increase

















0.5% 3.7% 2.2% 48.5%
0.4% 5.6% 2.2% 73.4%
2.7% 5.6% 5.0% 51.5%
Figure 5 DNA damage induced by MK-1775 and MK-8776 is present in S-phase cells. A2058, HT-29, and LoVo cells were treated for
24 hours as in Figure 4 with DMSO or concentrations of MK-1775 and/or MK-8776 indicated. Cells were stained for DNA content (x-axis) and
γH2AX (y-axis). γH2AX-positive cells are outlined and percentage of γH2AX-positive cells is indicated.
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Quantitation of the IHC results (Figure 7C) shows that
this is true of both the γH2AX as well as the phospho-
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Figure 6 DNA damage response incurred by MK-1775 and MK-8776 i
cells were treated with concentrations of MK-1775 and MK-8776 described
harvested and lysates analyzed by Western blot for caspase-dependent cle
30 minutes with either DMSO or the indicated concentration of CDK inhibi
concentrations of MK-1775 and MK-8776 used in Figures 3 and 4 (125 nM
300 nM MK-8776 in HT-29, and 40 nM MK-1775 plus 75 nM MK-8776 in LoV
harvested and lysates analyzed by Western blot for phosphorylated CHK1S3
treated for 2 hours with 75 nM MK-1775 alone or in combination with 150
by Western blot for the proteins and phosphoproteins indicated.In vivo xenograft efficacy from WEE1 and CHK1 inhibition
Combination of MK-1775 and MK-8776 induces greater-
than-additive DNA damage both in vitro (Figure 4) and
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for Figure 4, or 1 uM nocodazole for control. After 24 hours, cells were
aved PARP (PARP*). B, A2058, HT-29, and LoVo cells were treated for
tor (SCH-727965). Following this pretreatment, further DMSO or
MK-1775 plus 150 nM MK-8776 in A2058; 125 nM MK-1775 plus
o) were added to the cells for an additional 2 hours before cells were
45, indicative of activated DNA damage response. C, LoVo cells were
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Figure 7 Cooperative induction of DNA damage in vivo by WEE1 and CHK1 inhibitors. LoVo xenograft tumor-bearing mice were treated
with 60 mpk MK-1775 BID for 2 days, 60 mpk MK-8776 BID for 2 days, or the combination of MK-1775 and MK-8776 each at 60 mpk BID for
2 days. Tumors were collected at 2, 24, and 48 hours following the final dose. A, LoVo tumor lysates were analyzed by Western blot for
pCHK1S345. B, Tumor sections were fixed and analyzed by immunohistochemistry (IHC). Representative images for γH2AX at 2 hours and 48 hours
post final dose are shown. C, Quantitative analysis of IHC for both phospho-CHK1S345 and γH2AX (n=3); one-way ANOVA analyses *P<0.05.
**P<0.01, ***P<0.001.
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of this combination was assessed in two xenograft models
of human cancer. We used LoVo colorectal cancer cells
(Figures 8A and 8B) and ES-2 ovarian carcinoma cells
(Figure 8C). Tumor-bearing animals received 2 day BID
dosing of (i) vehicle only, (ii) MK-1775 (50 mpk) plus ve-
hicle, (iii) MK-8776 (50 mpk) plus vehicle, or (iv) MK-
1775 (50 mpk) plus MK-8776 (50 mpk).
Treatment with either MK-8776 or MK-1775 alone had
a modest effect on growth in LoVo xenografts, resulting
in 28% or 41% tumor growth inhibition (TGI), respectively
(Figure 8A). Based on the single agent treatment arms, the
Bliss independent (BI) model predicts 58% TGI for addi-
tive effects of combination (see Methods). However, at the
same doses and schedule used for each single agent, the
combination of MK-1775 and MK-8776 resulted in 91%
TGI. However, these LoVo xenograft tumors resumed
growth shortly after drug treatment was stopped
(Figure 8B). In the ES-2 xenograft study, the same treat-
ment schedules of MK-8776 and MK-1775 resulted in 1%
and 16% TGI, respectively. We observed 57% TGI in the
combination treatment arm, which was a notable 40%
above the 17% TGI predicted for the combination by the
BI model if the two drugs acted additively. Mean body
weight loss for the combination treatment group in either
study did not exceed 8%, and even then only for initial
and not subsequent doses, indicating that efficacy wasachieved at tolerated drug combination exposures (data
not shown). These data support the notion that combined
inhibition of WEE1 and CHK1 achieves in vivo synergy
and highlights the potential of this unique drug combin-
ation in the treatment of human neoplasms.
Conclusions
Using small molecule inhibitors currently under early clin-
ical development, we have shown that simultaneous inhib-
ition of the WEE1 and CHK1 kinases results in synergistic
potentiation of each drug for a variety of cell types in pro-
liferation assays. Knockout of WEE1 results in embryonic
lethality before day 3.5 [17], and knockdown of WEE1 is
known to inhibit proliferation of several cancer cell lines
in vitro [27,28]. Similarly, anti-proliferative effects of
CHK1 inhibition via siRNA or pharmacologic inhibition
have been described [30]. The increased potency of MK-
1775 and MK-8776 when combined supports the notion
that WEE1 and CHK1 have non-overlapping activity. Po-
tentially predictive biomarkers for each class of drug have
been described for their chemosensitizing effects, includ-
ing p53 status for both WEE1 and CHK1 [2,31], WEE1 ex-
pression levels for WEE1 [28], and cyclin B levels for
CHK1 [32]. Interestingly, synergy between MK-1775 and
MK-8776 did not correlate with the p53 status of the cell
line, though overall sensitivity to the drugs might favor











































































Figure 8 Activity of MK-8776 (i.p.) and MK-1775 (p.o.) in LoVo xenograft bearing mice. A, Each compound, alone or in combination, was
dosed at 50 mg/kg BID for 2 days per week over 4 weekly cycles and is indicated with arrows at the bottom of the graph. Control and single
agent groups received both or one vehicle, respectively, so that all animals were dosed with equal vehicle volume and frequency. Percent TGI
was calculated as 100 * ΔT/ΔC if ΔT > 0 where ΔT = final mean volume – initial mean volume of treated group, ΔC = final mean volume – initial
mean volume of vehicle control group, and Ti = initial mean volume of treated group. P value was derived by student’s t-test for combination
(n=10) versus MK-1775 treated tumors (n=10) on day 26. B, In the same study described in (A), LoVo tumor growth was tracked through study
day 56 following the fourth and final treatment cycle on days 22 and 23. C, ES-2 xenograft tumors were treated as in (A) for 3 treatment cycles,
and days of drug administration are indicated by arrows at the bottom of the graph. P value was derived by student's t-test for combination
(n=10) versus MK-1775 treated tumors (n=10) on day 18.
Guertin et al. Cancer Cell International 2012, 12:45 Page 9 of 12
http://www.cancerci.com/content/12/1/45described in Figure 1 are wild type for p53 (A2780, LoVo,
and A427). Further examination of other putative markers
such as expression of WEE1, CHK1, or cyclin B1, will be
important future questions to address in understanding
the cellular context of WEE1 and CHK1 inhibitor activity.
Mechanistic studies suggest that WEE1 and CHK1 inhi-
bitors combine synergistically due to, at least in part,
alterations of the cell cycle and compounded DNA dam-
age (Figures 2, 3, and 4). Though both MK-1775 and MK-
8776 are chemosensitizers that potentiate the anti-
proliferative effects of DNA damaging chemotherapeutics,
it is also known that knockdown or inhibition of either
WEE1 or CHK1 alone leads to DNA damage. Therefore,
it is likely that MK-1775 and MK-8776 work together in
an analogous fashion as they do in combination with gen-
otoxic agents to prevent proper checkpoint response and
damage control. Importantly, DNA damage incurred by
WEE1 and CHK1 inhibition occurs primarily in S phaseand requires CDK activity, consistent with findings that
disruption of either WEE1 or CHK1 individually leads to
S-phase arrest, slowed DNA replication, and induced
DNA damage. Increased accumulation and duration of
DNA damage by MK-1775 and MK-8776 was observed
in vivo, and accordingly the combination led to inhibition
of tumor growth in xenograft models. WEE1 and CHK1
inhibition was unable to prevent tumor regrowth, how-
ever, suggesting either that not all cells are affected or that
following drug treatment cells are able to sufficiently re-
pair damaged DNA. Along these lines, we were unable to
find robust evidence of apoptosis both in vitro and in vivo
(data not shown).
The WEE1 inhibitor MK-1775 is known to reduce phos-
phorylation on tyrosine 15 of CDK1/2, resulting in
increased CDK1/2 activity [26]. Inhibition of CHK1
increases the activity of the protein phosphatases
CDC25A/B/C, thereby reducing phosphorylation of
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hypothesized, therefore, that combined inhibition of
WEE1 and CHK1 could result in an additive inhibition of
phospho-CDK1/2Y15. However, we were unable to observe
a substantial decrease in phospho-CDK1/2Y15 beyond the
effect of MK-1775 alone, suggesting that CHK1 inhibition
by MK-8776 compliments inhibition of WEE1 through
mechanism(s) and target(s) distinct from CDK1/2.
The synergistic antiproliferative effect of combined
WEE1 and CHK1 inhibition was also noted by Davies
et al. [33] and Carrassa L et al. [34]. Each of these studies
identified the WEE1 gene as an siRNA target that could
sensitize to either a CHK1 inhibitor (Davies et al.) or a
CHK1 siRNA (Carrassa et al.) in solid tumor cell lines.
Davies et al. reported synergy between WEE1 and CHK1
inhibitors in four cell lines, three of which are reported
p53 wild type [33]. Similarly, Carrassa et al. reported syn-
ergy in seven cell lines regardless of p53 status [34]. This
manuscript extends earlier findings into 37 cancer cell
lines using compounds that are currently under early stage
clinical development. Our findings align with those
reported demonstrating that the mechanism underlying
synergy between WEE1 and CHK1 inhibition is ubiqui-
tous as well as with the finding that p53 status does not
affect this synergy.
Davies et al. reported an absence of premature mitosis
in the HEL92.1.7 cell line, though this experiment was
conducted with an excess of WEE1 and CHK1 inhibitors
required for inhibition of cell proliferation (compare
Figures 2C and 5 in [33]). Carrassa et al. conducted mech-
anistic studies in one cell line, OVCAR-5, and concluded
that premature mitosis accompanied the simultaneous in-
hibition of WEE1 and CHK1 inhibition [34]. It was un-
clear in that study whether concentrations of inhibitors
used to study biochemical correlates coincided with the
concentrations required to inhibit proliferation. By exam-
ining the effects of MK-1775 and MK-8776 at the lowest
concentrations needed to achieve antiproliferative activity,
individualized for multiple cell lines, we are able to dem-
onstrate that DNA damage rather than premature mitosis
seems to be the primary cause of synergistic cytoxicity
(Figure 4), though we do find that select cell lines, i.e. HT-
29, may undergo premature mitosis as well. Importantly,
these findings were corroborated in vivo where LoVo
xenograft tumor samples demonstrated synergistic
increases in the DNA damage markers γH2AX and
pCHK1S345 but not in the mitosis marker pHH3 (Figure 7
and data not shown). Collectively these data argue that
nonoverlapping functions of the WEE1 and CHK1 kinases
during S- phase are responsible for the widespread and
strong synergy observed following their inhibition.
Our studies describe synergy achieved by simultaneous
inhibition of the WEE1 and CHK1 kinases and, together
with the work of Davies et al. [33] and Carrassa et al. [34],provide pharmacologic evidence that the two kinases have
unique and nonoverlapping activities. Combined treat-
ment with MK-1775 and MK-8776 demonstrates synergis-
tic DNA damage and anti-tumor efficacy at tolerated
doses, suggesting possible clinical use of the drugs in com-
bination. The robust and ubiquitous nature of the synergy
may suggest potential toxicity in normal tissue and there-
fore identification of mechanisms underlying sensitivity
will be important in understanding the potential clinical
application of this combination.
Methods
Cell culture and compounds
All cell lines were obtained from American Type Culture
Collection, except A2780 cells which were obtained from
Sigma, and cultured under vendors’ recommended condi-
tions. The HCT116 and RKO isogenic cell lines were
obtained from Horizon Discovery, LTD. The chemical
name of MK-1775 is (2-allyl-1-[6-(1-hydroxy-1-methy-
lethyl) pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl) phenyl]
amino}-1,2-dihydro-3H-pyrazolo[3,4-d] pyrimidin-3-one),
and its chemical structure is described elsewhere [26].
The chemical name of MK-8776 is (R)-(−)-6-Bromo-3-
(1-methyl-1H-pyrazol-4-yl)-5-piperidin-3-yl-pyrazolo[1,5-a]
pyrimidin-7-ylamine and has been described previously as
SCH-900776 [35]. SCH-727965 has also been previously
described in the literature [29].
Cell viability assay
For each experiment, cells were seeded in duplicate 96-
well white walled plates at 4,000 cells per well. After over-
night incubation, cells were treated with combinations
of DMSO as vehicle control, MK-1775, and MK-8776 for
72 hours. Cell viability was determined by measuring ATP
with Vialight Plus (Lonza) according to manufacturer’s
instructions. Drug potency was calculated as the ratio of
relative light units (RLUs) in compound treated wells over
DMSO-treated control wells and expressed as % DMSO
control. Compound EC50s were calculated in GraphPad
Prism using a 4 parameter variable slope sigmoidal dose
response curve fit.
Flow cytometry
Cells were treated with indicated concentrations of MK-
1775, MK-8776, both, or an equivalent volume of vehicle
for a fixed time period. At time of harvest, cells were
counted and then fixed in ice cold 70% ethanol overnight
before staining with anti-phospho-histone H2AX (S139;
γH2AX) antibody conjugated to FITC (from Millipore kit
17–344), anti-phospho-histone H3 (S28; pHH3) antibody
conjugated to Alexa FluorW 647 (BD Biosciences 558217),
and propidium iodide (BD Biosciences 550825). Samples
were read on the LSR II (BD Biosciences 347545) flow
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version 7.5.5.
Animals and xenograft studies
CD-1 Nu/Nu female mice aged 5–6 weeks were obtained
from Charles River Laboratories and housed in our animal
care facility at standard laboratory conditions and fed
2018S autoclaveable diet and water ad libitum. The proto-
col was approved by Merck’s Institutional Animal Care
and Use Committee. Mice were inoculated with 5 x 106
LoVo cells in 100 μL (1:1 Matrigel:PBS) subcutaneously
(S.C.) into the right flank. When tumor volume reached
200 mm3 (+/−50) mice were pair-matched so each group
had a similar mean and standard deviation. Tumor vol-
ume and body weights were recorded bi-weekly. Mice
received 4 treatment cycles of twice daily dosing (BID) for
2 days receiving either vehicle, MK-1775 (50 mpk), and/or
MK-8776 (50 mpk) For pharmacodynamic assays, mice
were dosed with 60 mpk of each compound.
In vivo pharmacodynamic assays
Xenograft tumors were fixed in 10% formalin, paraffin-
embedded and sectioned at 5 μm. Tumor sections were
immunostained with rabbit monoclonal anti-phospho-
CHK1 (S345) antibody (1:300 dilution; Cell Signaling);
rabbit polyclonal anti-gamma-histone H2AX antibody
(1:2000 dilution; Bethyl); rabbit polyclonal anti-phospho-
CDC2 Y15 antibody (1:960; R&D Systems) and rabbit
monoclonal anti-Ki67 antibody (1:200; Epitomics). Labeled
antigens were visualized using Omni Map anti-rabbit HRP
and peroxidase substrate (Ventana Medical Systems). Slides
were digitized using an Aperio ScanScope XT Image Sys-
tem and immunostained cells were quantified using Aperio
Imagescope software. The percentage of cells showing
immunostaining in each tumor was calculated relative to
the number of total cells with necrotic regions excluded.
Bliss synergy calculations
The Bliss independence (BI) model is used to define the ef-
fect of two drugs assumed to act through independent
mechanisms [36]. BI is described by the equation Ei = (EA +
EB) - (EA x EB), where Ei is the predicted effect (percentage
of inhibition) by the combination of drugs A and B if they
were to act additively and independently, and EA and EB are
the observed effects (percentage of inhibition) of each drug
alone, respectively. When observed inhibition exceeds pre-
dicted inhibition, the two compounds are considered to act
synergistically.
Additional files
Additional file 1: Figure S1. Synergistic interaction of MK-1775 and
MK-8776 in 39 solid tumor cell lines. A, Cell lines are grouped according
to cancer type. Observed synergy is reported for each line as vBliss,which is the volumetric difference between the surface of predicted
combination effect and the surface of observed combination effect as
illustrated in parts B and C, (see Methods for explanation of Bliss synergy
predictions). B, The A2058 melanoma cell line is an example of synergy.
Four concentrations each of MK-1775 and MK-8776 were titrated and
proliferation at 96 hours was plotted as a fraction of DMSO treated
control A2058 cells. The predicted effect on proliferation (using Bliss
synergy model) is represented as the upper surface on the plot whereas
the observed effect on proliferation is represented by black dots.
Observed effects are connected by vertical lines to the corresponding
Bliss predicted effect for those concentrations. C, As in part B but
showing the KPL1 cell line as an example of lack of synergy between
MK-1775 and MK-8776.
Additional file 2: Figure S2. Synergistic interaction of MK-1775 and
MK-8776 in primary human renal epithelial (HRE) cells. A, Proliferation
assay results (72 hours) in HRE cells showing the WEE1 inhibitor MK-1775
titrated in addition to either vehicle (DMSO), or the indicated fixed
concentration of the CHK1 inhibitor, MK-8776 (compare to Figure 1).
B, Proliferation assay results (72 hours) in HRE cells exposed to 8-point
titrations of both MK-1775 (starting 4 μM then 1-to-3 dilutions) and MK-
8776 (starting 10 μM then 1-to-3 dilutions) are expressed as surface plots
for Bliss predicted additivity and actual observed response (compare to
Additional file 1: Figures S1B and S1C). The observed vBliss was 0.06
(compare to Additional file 1: Figure S1A).
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